14
May

For years, the FDA has been unveiling its plan for regulating knockoffs of blockbuster biologics in fits and starts, this week outlining just how it wants to define biosimilarity for would-be copycat drugs.

…read more

Source: FDA breaks silence on biosimilars with long-awaited proposal

    

0 No comments